- Home
- CPBI vs ALXO Comparison
CPBI vs ALXO Comparison
Compare CPBI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | ALXO |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 68.3M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPBI | ALXO |
|---|---|---|
| Price | $17.77 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | 3.9K | ★ 998.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.02 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.00 | $0.41 |
| 52 Week High | $17.87 | $2.66 |
Technical Indicators
Market Signals| Indicator | CPBI | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 52.41 |
| Support Level | $17.37 | $1.41 |
| Resistance Level | N/A | $2.27 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 80.00 | 23.08 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.